Researchers investigate link between autoimmune diseases and wounds that don’t heal

 

Washington, DC (December 15, 2011) – Millions of Americans suffer from wounds that don’t heal, and while most are typically associated with diabetes, new research has identified another possible underlying cause – autoimmune diseases. The finding, published online Dec. 14th in the International Wound Journal, represents an unappreciated link that could lead to important new insights in wound healing, say researchers at Georgetown University Medical Center. (Data from this study were presented at the 2011 annual meeting of the American College of Rheumatology.)

 

The study was sparked by the keen observation of Georgetown rheumatologist Victoria Shanmugam, M.D., who began noticing something rather unusual in her patients with autoimmune diseases — any open wound they had was very slow to heal. Their recovery was even more protracted than in patients with wounds who have diabetes, a disease that is notoriously damaging to blood vessels and to normal skin repair.

 

So Shanmugam and her colleagues conducted a chart review of people who sought care at a high-volume wound clinic at Georgetown University Hospital to determine the prevalence of autoimmune diseases. The study included patients with open wounds — usually leg ulcers who were treated during a three-month period in 2009. Of the 340 patients, 49 percent had diabetes, which she says is a typical rate.

 

"But what was surprising is that 23 percent had underlying autoimmune diseases, and the connection between these relatively rare disorders and wounds that don’t heal is under-recognized," she says.

 

Of the 78 patients in the cohort who had autoimmune disease, most had rheumatoid arthritis, lupus or livedoid vasculopathy, a type of vascular disease.

 

Shanmugam says her findings also show that autoimmune disease-associated wounds were significantly larger at the patient’s first visit. These non-healing wounds can be "incredibly emotionally draining and financially costly," Shanmugam says, because they require doctor visits over many months as well as an ever-present risk of serious infections. Sometimes, infections can lead to surgery and the amputation of limbs. More often, they require skin grafts or use of skin substitutes, which may still not solve the problem.

 

In fact, Shanmugam’s study found that skin grafts were more likely to fail in patients with autoimmune disease-associated wounds.

 

Shanmugam hopes the link she has made between autoimmune diseases and wound healing will make its way into the consciousness of the general practitioner. While it is much too invasive and costly to recommend that all patients with wounds be tested for autoimmune diseases, she says, "If a doctor has a patient with a leg ulcer that won’t heal after three or four months and they have done all the appropriate treatments, I hope they will look for the presence of an autoimmune disorder."

 

 

Shanmugam’s research is funded by a KL2 Mentored Career Development Program Scholar grant from Georgetown-Howard Universities Center for Clinical & Translational Science. The Center was established in 2010 and is funded by a National Institutes of Health Clinical and Translational Science Award. The KL2 grant funds junior faculty members starting translational research programs.

 

 

About Georgetown University Medical Center

 

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis — or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university’s sponsored research funding.

 

 


Georgetown University Medical Center, 15.12.2011 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…